Shortened Liver MRI Protocol Shows Strong Accuracy for Spotting Tumor Return After Ablation

Liver cancer specialists may soon have a faster, cheaper way to keep watch over patients after their tumors have been destroyed by heat. A new study from researchers at the David Geffen School of Medicine at UCLA, published in the open-access journal CVIR Oncology, reports that a dramatically shortened magnetic resonance imaging protocol can detect recurrent hepatocellular carcinoma after microwave ablation with accuracy approaching that of full-length MRI scans. The finding could reshape how clinicians around the world schedule the relentless follow-up imaging that liver cancer survivors must undergo for the rest of their lives.

Hepatocellular carcinoma, the most common form of primary liver cancer, is a disease of vigilance. Even when a tumor is successfully eliminated, the underlying cirrhotic liver that produced it remains fertile ground for new malignancies, and recurrence can appear either at the ablation site or anywhere else in the organ. International guidelines from the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, and the Korean Liver Cancer Association therefore recommend serial imaging every three to six months after treatment, a schedule patients typically maintain indefinitely. Missing an early recurrence can mean the difference between another curative intervention and advanced, incurable disease.

The standard surveillance toolkit has long been a compromise. Computed tomography with intravenous contrast exposes patients to cumulative radiation and carries risks of contrast allergy and kidney injury, making it a suboptimal choice for patients who may need dozens of scans over a lifetime. Complete-protocol MRI with gadolinium-based contrast is widely considered the best imaging modality for detecting and characterizing hepatocellular carcinoma, but it is constrained by long scan times, high cost, limited scanner access, and the specialized expertise required to interpret dozens of image series. That bottleneck has motivated radiologists to ask a deceptively simple question: how much of the full scan is actually necessary?

The UCLA team, led by Pedram Keshavarz and senior authors Steven S. Raman and David S. K. Lu, tested an abbreviated MRI protocol built around just two sequences: the hepatobiliary phase of a gadoxetic acid-enhanced scan and a single-shot T2-weighted sequence. Gadoxetic acid is a liver-specific contrast agent, roughly half of which is excreted through the bile after injection. In the late hepatobiliary phase, typically captured fifteen to twenty minutes after administration, functioning hepatocytes take up the agent through organic anion transporting polypeptide transporters on their surface and appear bright. Most hepatocellular carcinomas lack these transporters, so tumors stand out as dark defects against the glowing liver, a contrast mechanism that makes the hepatobiliary phase exceptionally sensitive for cancer detection.

To evaluate the shortened protocol, the researchers assembled a retrospective cohort of 43 patients, mean age about 70 years and overwhelmingly male, who had undergone percutaneous microwave ablation for naive hepatocellular carcinoma at a tertiary care liver transplant center between January 2017 and December 2019. Nearly all had cirrhosis, most commonly from chronic hepatitis C or alcoholic liver disease. The cohort yielded 215 complete gadoxetic acid-enhanced surveillance MRI exams. Twenty-seven consecutive patients with recurrence contributed 48 positive and 86 negative exams, and 16 randomly selected patients without recurrence added another 81 negative exams, deliberately enriching the dataset with negative studies to approximate real-world screening conditions. Three board-certified abdominal radiologists, blinded to all clinical information, then independently reviewed the abbreviated versions of each exam, comparing them against the original full-protocol reports, which served as the reference standard.

The results were striking. On a per-patient basis, the abbreviated protocol achieved pooled sensitivity of 86.4 percent, specificity of 100 percent, and a negative predictive value of 88.1 percent for detecting recurrence of any type. Analyzed exam by exam, the numbers were 87.5 percent sensitivity, 97.6 percent specificity, and 93.3 percent negative predictive value, with an area under the receiver operating characteristic curve of 0.90. For recurrences confined to the ablation zone, per-patient sensitivity was 85.7 percent with perfect specificity, while for recurrences elsewhere in the liver the protocol detected 86.6 percent of cases, also with perfect specificity, though the negative predictive value for these distant recurrences dipped to 72.4 percent. Perhaps most impressive was the consistency between readers: inter-reader agreement was excellent, with a kappa of 0.91 per patient, comparable to the agreement reported for full-protocol interpretation of treated lesions.

The failures of the abbreviated scan were as informative as its successes. Across 645 readings, only three false positives occurred, attributable to motion artifact mimicking a nodule, a siderotic regenerative nodule, and a benign pseudolesion, all of which would likely be resolved by a confirmatory full MRI in clinical practice. False negatives were more numerous, eleven in total, and clustered around small recurrences measuring roughly 10 to 16 millimeters that showed arterial hyperenhancement on the complete scan but were invisible or only partially visible as defects on the hepatobiliary phase. A small minority of hepatocellular carcinomas, estimated at 5 to 10 percent, retain the transporter expression that makes them take up gadoxetic acid, the so-called green hepatocellular carcinomas, and these can evade detection on hepatobiliary-phase imaging alone.

The study builds on a growing body of evidence that abbreviated MRI works for primary screening of at-risk cirrhotic patients, where gadoxetate-enhanced abbreviated protocols have reported sensitivities in the low 80 percent range. What distinguishes the new work is its focus on secondary surveillance, the follow-up of patients already treated for hepatocellular carcinoma, a setting with far fewer published data. A Korean study by Jeon and colleagues previously found no significant difference between abbreviated and full-protocol MRI for detecting post-treatment recurrence, with per-patient sensitivity of 73.1 percent for the abbreviated approach, and the UCLA results, with higher sensitivity, reinforce the case that trimming the protocol does not meaningfully compromise cancer detection.

The clinical implications are considerable. A surveillance exam consisting of two sequences instead of the full multiphasic battery could shorten scanner time substantially, reduce per-exam cost, and expand access for the many patients who currently face months-long waits for liver MRI. Because a negative abbreviated scan reliably excludes recurrence, the authors argue, it could spare patients unnecessary comprehensive imaging, lowering both healthcare expenditure and patient burden. A positive abbreviated scan, meanwhile, would simply trigger a confirmatory complete MRI, meaning false positives carry less clinical harm than false negatives. The researchers also point to the horizon: deep learning reconstruction is already being used to denoise images and cut scan times further, and experimental synthetic contrast techniques have produced gadolinium-free contrast-enhanced MRI in as little as four minutes, compared with 28 minutes for standard protocols.

The authors are careful to note the caveats. The study was retrospective, the enriched proportion of recurrence-negative exams does not reflect a true clinical population, no formal cost or time savings were quantified, the abbreviated protocol omitted diffusion-weighted imaging, and exams spanned both 1.5 and 3 Tesla scanners. Larger prospective and multicenter trials will be needed before abbreviated protocols become standard practice. Still, for the hundreds of thousands of patients worldwide who live under the shadow of hepatocellular carcinoma recurrence, the message is hopeful: the future of surveillance may be shorter, safer, and just as sharp.

Subject of Research: Abbreviated hepatobiliary phase MRI for surveillance of hepatocellular carcinoma recurrence after microwave ablation

Article Title: Hepatobiliary phase abbreviated MRI for secondary surveillance after microwave ablation of HCC

Article References: Keshavarz, P., King, K. G., Depetris, J., Quirk, M., Kang, T. W., Sayre, J., Tong, M. J., McWilliams, J. P., Raman, S. S., & Lu, D. S. K. (2025). Hepatobiliary phase abbreviated MRI for secondary surveillance after microwave ablation of HCC. CVIR Oncology, 1(1), Article 6. https://doi.org/10.1007/s44343-025-00007-1

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00007-1

Keywords: hepatocellular carcinoma, abbreviated MRI, hepatobiliary phase, microwave ablation, secondary surveillance, gadoxetic acid, liver cancer recurrence, radiology, medical imaging, cirrhosis, negative predictive value, deep learning MRI